LAUSR

Objectives: Vascular dementia (VaD) is a heterogeneous brain disorder for which there are no effective approved pharmacological treatments available. We aimed to evaluate theeffect of Levamlodipine Besylate in the treatment of vascular dementia on cognitive impairment in mice after eight weeks-right unilateral common carotid arteriesocclusion (rUCCAO). Methods: Levamlodipine Besylate (0.1 or 0.5 mg/kg) was given to rUCCAO mice for eight weeks. Administration of Levamlodipine Besylate (0.1 mg/kg) reduced escape latency in space exploration and working memory test compared with the vehicle group. Results: Vehicle-treated mice showed reduced phospho-CaMKII (Thr286) levels in the hippocampus, whereas partially restored by Levamlodipine Besylate (0.1 mg/kg) treatment. No significant effect on microglia and astrocyte activation was observed following Levamlodipine Besylate (0.1 mg/kg) treatment. Conclusion: These data disclose novel findings about the therapeutic potential of low-dose Levamlodipine Besylate significantly enhanced the cognitive function in VaD mice.